Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.

Abstract excerpt

Uncommon EGFR mutations represent a rare subgroup of NSCLC. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in these rare mutations are scattered and limited to mostly retrospective small cohorts because these patients were usually excluded from clinical trials. This was a systematic review on the efficacy of TKIs in patients harboring uncommon EGFR mutations, defined as...

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• ErbB Receptors
• EGFR gene
• Lung Neoplasms
• Mutation